GET DAILY SIGNALSProfound Medical Corp. (PROF): Path to the $11 Analyst Target
Key Takeaways
- The central target examined here is $11, the arithmetic mean of three verifiable current analyst price targets.
- The reviewed analyst targets span a tight range of $10 to $12, with the stock trading near $7.44 at the time of writing.
- Reaching $11 would require a gain of roughly 48% from the latest price.
- Support comes from a strong Buy consensus, expanding commercial adoption of TULSA-PRO, and the stock's position above key moving averages.
- Key risks include persistent net losses, competition in prostate treatment, and potential valuation compression after a sharp recent rally.
- For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages for deeper coverage and data.
- Explore Trending AI Robots to see how AI-driven tools are monitoring stocks like PROF in real time.
Analyst Price Targets and Consensus View
Profound Medical Corp. (PROF) is not yet profitable, which helps explain why coverage remains relatively light. Still, three firms have published current targets in U.S. dollars: Stifel Nicolaus at $10, Raymond James at $11, and Lake Street at $12. Their average comes to $11.00, and that figure anchors the discussion here. All three ratings are Buys, a clean consensus that stands out for a small-cap device company. Earlier, more aggressive targets such as the $15.25 from 2025 have aged out and are set aside. The narrow band shows analysts largely see the same commercial runway even if their exact numbers differ a bit.
Current Market Position and Path Toward the Target
At the most recent close the shares sat near $7.44, inside a 52-week range of $4.80 to $8.95. Closing the gap to $11 would mean an advance of roughly 48%. Because earnings are still negative, that move hinges on continued revenue growth from the TULSA-PRO system and the newer Sonalleve line rather than near-term profits. Recent quarterly results showed a wider loss than some expected, underscoring that scaling sales and managing costs remain the key variables.
What Could Support a Move Toward the Target
- Product adoption: TULSA-PRO delivers an incision-free, MRI-guided option for prostate ablation, tapping a sizable and expanding patient base.
- Unanimous Buy consensus: Every current analyst rates the stock a Buy, with targets comfortably above the present price.
- Revenue trajectory: Management is guiding for solid top-line growth, and analysts expect losses to narrow as volumes rise.
- Technical position: The shares trade above both the 50-day and 200-day moving averages, a sign of improving momentum.
What Could Prevent the Target From Being Reached
- Ongoing losses: The company remains unprofitable, and any EPS misses can pressure sentiment.
- Competition: Established surgical and other energy-based treatments compete in the prostate space.
- Valuation after a rally: After rebounding from $4.80, the stock could see profit-taking if growth slows.
- Thin coverage: With only a few analysts active, targets can shift more readily than they do for larger names.
Technical Levels and Market Structure
The 52-week low at $4.80 and high at $8.95 remain the clearest reference points. Clearing the high would mark a multi-year peak and open the door to the $10-to-$12 zone. On the downside, the 50-day average near $6.30 and the 200-day average near $6.65 offer nearby support, along with the $6 psychological level. Holding above these averages would reinforce the durability of the recent uptrend. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the technical setup.
Time Horizon and What Investors Should Monitor
Analyst targets typically look out about twelve months. For PROF, the main catalysts ahead are quarterly revenue updates, progress on TULSA-PRO reimbursement and hospital adoption, and any revisions to estimates. Because the story centers on revenue scaling, investors will likely focus on gross margins, cash usage, and new account traction more than on EPS, which is expected to stay negative for now.
My Take on the Outlook
Whether PROF can reach $11 rests on sustaining revenue growth, narrowing losses, and retaining confidence after the recent rally. The $11 mean comes from a tight $10-to-$12 analyst band and implies a meaningful advance from current levels. Unanimous Buy ratings and a constructive technical picture provide the main support, while ongoing losses and the chance of consolidation after a fast rise represent the chief hurdles. With earnings and commercial milestones still to come, the target is a grounded, analyst-based benchmark rather than a guaranteed near-term outcome.
Using Tickeron’s AI Daily Buy/Sell Signals in My Process
I rely on Tickeron’s AI Daily Buy/Sell Signals to track how market conditions and technical factors shift for stocks like PROF. The tool scans thousands of names continuously and flags Buy, Sell, or Hold ideas based on AI analysis. It serves as a practical complement to fundamental work when I want a timely, data-driven view of trend changes and position management.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PROF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PROF turned positive on October 30, 2026. Looking at past instances where PROF's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PROF as a result. In 64 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
PROF moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PROF crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +6.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROF advanced for three days, in 198 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 111 of 149 cases where PROF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PROF broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. PROF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.289) is normal, around the industry mean (4.142). P/E Ratio (-7.283) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.194) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturee of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology
Industry MedicalNursingServices
Advertisement